Ehlers-Danlos syndrome, an underreported consideration in plastic surgery: A narrative review of cases
Abstract
Background: Ehlers-Danlos Syndrome (EDS) encompasses a variety of collagen disorders characterized by joint hypermobility, skin laxity, and tissue fragility. Evidence to guide plastic surgeons for both elective and reconstructive procedures is limited and consists predominantly of case reports and series. As higher-level comparative data are scarce, synthesizing case-level data remains essential to understand surgical risks, considerations, and postoperative outcomes in this patient population.
Methods: A narrative review of case reports and series was conducted using PRISMA guidelines across Scopus, PubMed/MEDLINE, Cochrane, Web of Science, and Embase. Studies from inception to September 2025 were screened for surgical management of patients with EDS. After screening 1816 abstracts with review of 230 full texts, 52 studies met inclusion criteria. Data were collected on demographics, EDS subtype, surgical indication, procedures, perioperative care, and complications. Case-level data were summarized descriptively as counts and percentages, with continuous variables reported as mean (SD) and median (range).
Results: The 52 studies described 77 individual cases of EDS, most frequently hypermobile (36.4%), classical (27.3%), and vascular (9.1%) subtypes. The cohort was predominantly female (female-to-male ratio 1.8:1), with a mean age of 31.9 ± 16.6 years (median 28, range 3-64). Reconstruction was the primary indication (67.5%), with additional representation from aesthetic…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.